{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T01:19:26Z","timestamp":1773364766459,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"2-3","license":[{"start":{"date-parts":[[2007,12,1]],"date-time":"2007-12-01T00:00:00Z","timestamp":1196467200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug and Alcohol Dependence"],"published-print":{"date-parts":[[2007,12]]},"DOI":"10.1016\/j.drugalcdep.2007.06.007","type":"journal-article","created":{"date-parts":[[2007,7,24]],"date-time":"2007-07-24T11:10:45Z","timestamp":1185275445000},"page":"269-278","source":"Crossref","is-referenced-by-count":75,"title":["Interaction between buprenorphine and atazanavir or atazanavir\/ritonavir"],"prefix":"10.1016","volume":"91","author":[{"given":"Elinore F.","family":"McCance-Katz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David E.","family":"Moody","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gene D.","family":"Morse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robin","family":"DiFrancesco","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerald","family":"Friedland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pade","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petrie M.","family":"Rainey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.drugalcdep.2007.06.007_bib1","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1128\/AAC.46.3.884-886.2002","article-title":"International interlaboratory quality control program for measurement of antiretroviral drugs in plasma","volume":"46","author":"Aarnoutse","year":"2002","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib2","doi-asserted-by":"crossref","unstructured":"Altice, F.L., Friedland, G.H., Cooney, E.L., 1999. Nevirapine-induced opiate withdrawal among injection drug users with HIV infection receiving methadone. 13, 957\u2013962.","DOI":"10.1097\/00002030-199905280-00012"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11606-002-0044-3","article-title":"Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users","volume":"17","author":"Arnsten","year":"2002","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib4","unstructured":"Bristol Myers Squibb: Reyataz (atazanavir) Prescribing information. PDR 948\u2013957, 2006."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1097\/01.aids.0000216384.22432.9a","article-title":"Three case reports of a clinical pharmacokinetic interaction with buprenorphine and atazanavir plus ritonavir","volume":"20","author":"Bruce","year":"2006","journal-title":"AIDS"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib6","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1097\/00002030-200109070-00015","article-title":"Time to initiating highly active antiretroviral therapy among HIV-infected injection drug users","volume":"15","author":"Celentano","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib7","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1124\/dmd.105.006148","article-title":"Novel metabolites of buprenorphine detected in human liver microsomes and human urine","volume":"34","author":"Chang","year":"2006","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl. 2","key":"10.1016\/j.drugalcdep.2007.06.007_bib8","doi-asserted-by":"crossref","first-page":"S39","DOI":"10.1016\/S0376-8716(03)00058-9","article-title":"Pharmacokinetics of the combination tablet of buprenorphine and naloxone","volume":"70","author":"Chiang","year":"2003","journal-title":"Drug Alcohol Depend."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/S0891-5520(02)00012-0","article-title":"HIV-1 infection in injection drug users","volume":"16","author":"Cohn","year":"2002","journal-title":"Infect Dis. Clin. North Am."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib10","unstructured":"Deany, P., 2000. HIV and injecting drug use: a new challenge to sustainable human development. Available at: http:\/\/www.undp.org\/hiv\/publications\/deany.htm. Accessed 30 May 2006."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib11","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1046\/j.1525-1381.1999.09248.x","article-title":"Treatment for drug dependence","volume":"111","author":"Des Jarlais","year":"1999","journal-title":"Proc. Assoc. Am. Physicians"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib12","series-title":"Diagnostic and Statistical Manual of Mental Disorders","year":"2000"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib13","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00126334-200303010-00007","article-title":"Evaluation of antiretroviral drug measurements by an interlaboratory quality control program","volume":"32","author":"Droste","year":"2003","journal-title":"J. Acquir Immune Defic. Syndr."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","article-title":"\u201cMini-mental state.\u201d A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"Folstein","year":"1975","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib15","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3109\/00952998709001515","article-title":"Two new rating scales for opiate withdrawal","volume":"13","author":"Handelsman","year":"1987","journal-title":"Am. J. Drug Alcohol Abuse."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib16","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1128\/AAC.48.3.824-831.2004","article-title":"Quality assurance program for clinical measurement of antiretrovirals: AIDS clinical trials group proficiency testing program for pediatric and adult pharmacology laboratories","volume":"48","author":"Holland","year":"2004","journal-title":"Antimicrob. Agent Chemother."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib17","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1097\/01.ftd.0000211817.58052.b8","article-title":"Quality assurance program for pharmacokinetic assay of antiretrovirals: ACTG proficiency testing for pediatric and adult pharmacology support laboratories, 2003 to 2004: a requirement for therapeutic drug monitoring","volume":"28","author":"Holland","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib18","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/01.ftd.0000197094.92559.b4","article-title":"The in vivo glucuronidation of buprenorphine and norbuprenorphine determined by liquid chromatography-eletrospray ionization-tandem mass spectrometry","volume":"28","author":"Huang","year":"2006","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib19","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1016\/S0024-3205(97)00160-4","article-title":"Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes","volume":"60","author":"Iribarne","year":"1997","journal-title":"Life Sci."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib20","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00007691-200306000-00015","article-title":"Reverse phase high performance liquid chromatography method for the analysis of amprenavir, efavirenz, indinavir, lopinavir, nelfinavir and its active metabolite (M8), ritonavir, and saquinavir in heparinized human plasma","volume":"25","author":"Keil","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib21","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/FTD.0b013e3180318ef3","article-title":"Integration of atazanavir into an existing liquid chromatography UV method for protease inhibitors: validation and application","volume":"29","author":"Keil","year":"2007","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib22","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1006\/abbi.1996.0320","article-title":"The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1","volume":"332","author":"King","year":"1996","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib23","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2165\/00003088-200443050-00003","article-title":"Pharmacokinetic enhancement of protease inhibitor therapy","volume":"43","author":"King","year":"2004","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00042560-200107010-00006","article-title":"Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection","volume":"27","author":"Lucas","year":"2001","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib25","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/10673220490905688","article-title":"Office-based buprenorphine treatment for opioid-dependent patients","volume":"12","author":"McCance-Katz","year":"2004","journal-title":"Harv. Rev. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib26","doi-asserted-by":"crossref","first-page":"S89","DOI":"10.1086\/429503","article-title":"Treatment of opioid dependence and coinfection with HIV and hepatitis C virus in opioid-dependent patients: the importance of drug interactions between opioids and antiretroviral medications","volume":"41","author":"McCance-Katz","year":"2005","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib27","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/10550490290088072","article-title":"Modified directly observed therapy for injection drug users with HIV disease","volume":"11","author":"McCance-Katz","year":"2002","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib28","doi-asserted-by":"crossref","first-page":"S224","DOI":"10.1086\/508187","article-title":"Interactions between buprenorphine and antiretrovirals I: non-nucleoside reverse transcriptase inhibitors efavirenz and delavirdine","volume":"43","author":"McCance-Katz","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib29","doi-asserted-by":"crossref","first-page":"S235","DOI":"10.1086\/508188","article-title":"Interactions between buprenorphine and antiretrovirals II: protease inhibitors, nelfinavir, lopinavir\/ritonavir, or ritonavir","volume":"43","author":"McCance-Katz","year":"2006","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib30","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1086\/376907","article-title":"The protease inhibitor lopinavir\/ritonavir may produce opiate withdrawal in methadone-maintained patients","volume":"37","author":"McCance-Katz","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib31","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/10550490490436037","article-title":"Drug interactions between opioid and antiretroviral medications: interaction between methadone, LAAM, and nelfinavir","volume":"13","author":"McCance-Katz","year":"2004","journal-title":"Am. J. Addict."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib32","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1097\/00002030-199714000-00002","article-title":"Potential factors affecting adherence with HIV therapy","volume":"11","author":"Mehta","year":"1997","journal-title":"AIDS"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib33","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/dmd.104.002931","article-title":"Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro","volume":"33","author":"Perloff","year":"2005","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib34","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1124\/dmd.30.12.1364","article-title":"Inhibition and active sites of UDP-glucuronosyltransferases 2B7 and 1A1","volume":"30","author":"Rios","year":"2002","journal-title":"Drug Metab. Dispos."},{"issue":"Suppl. 20","key":"10.1016\/j.drugalcdep.2007.06.007_bib35","first-page":"22","article-title":"The mini-international neuropsychiatric interview (M.I.N.I): the development and validation of a structured diagnostic interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib36","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/00004714-199602000-00010","article-title":"Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index","volume":"16","author":"Strain","year":"1996","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib37","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1001\/jama.280.6.547","article-title":"Barriers to use of free antiretroviral therapy in injection drug users","volume":"280","author":"Strathdee","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib38","series-title":"WinNonLin Professional, Version 5.0","year":"2005"},{"key":"10.1016\/j.drugalcdep.2007.06.007_bib39","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1124\/dmd.105.005447","article-title":"In vitro inhibition of UDP glucuronosyltransferases by atazanavir and other HIV protease inhibitors and the relationship of this property to in vivo bilirubin glucuronidation","volume":"33","author":"Zhang","year":"2005","journal-title":"Drug Metab. Dispos."}],"container-title":["Drug and Alcohol Dependence"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871607002463?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0376871607002463?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,25]],"date-time":"2020-04-25T09:33:02Z","timestamp":1587807182000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0376871607002463"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,12]]},"references-count":39,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2007,12]]}},"alternative-id":["S0376871607002463"],"URL":"https:\/\/doi.org\/10.1016\/j.drugalcdep.2007.06.007","relation":{},"ISSN":["0376-8716"],"issn-type":[{"value":"0376-8716","type":"print"}],"subject":[],"published":{"date-parts":[[2007,12]]}}}